

Critical Review

Assay Sensitivity of Pain Intensity Versus Pain Relief in Acute Pain Clinical Trials: ACTION Systematic Review and Meta-Analysis

Neil Singla,^{*} Matthew Hunsinger,[†] Phoebe D. Chang,^{*} Michael P. McDermott,[‡] Amit K. Chowdhry,[‡] Paul J. Desjardins,[§] Dennis C. Turk,[¶] and Robert H. Dworkin^{||}

^{*}Lotus Clinical Research, Huntington Hospital, Department of Anesthesiology, Pasadena, California.

[†]School of Professional Psychology, Pacific University, Hillsboro, Oregon.

Departments of [‡]Biostatistics and Computational Biology and ^{||}Anesthesiology, University of Rochester, Rochester, New York.

[§]Desjardins Associates, LLC, Maplewood, New Jersey.

[¶]Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.

Abstract: The magnitude of the effect size of an analgesic intervention can be influenced by several factors, including research design. A key design component is the choice of the primary endpoint. The purpose of this meta-analysis was to compare the assay sensitivity of 2 efficacy paradigms: pain intensity (calculated using summed pain intensity difference [SPID]) and pain relief (calculated using total pain relief [TOTPAR]). A systematic review of the literature was performed to identify acute pain studies that calculated both SPIDs and TOTPARs within the same study. Studies were included in this review if they were randomized, double-blind, placebo-controlled investigations involving medications for post-surgical acute pain and if enough data were provided to calculate TOTPAR and SPID standardized effect sizes. Based on a meta-analysis of 45 studies, the mean standardized effect size for TOTPAR (1.13) was .11 higher than that for SPID (1.02; $P = .01$). Mixed-effects meta-regression analyses found no significant associations between the TOTPAR – SPID difference in standardized effect size and trial design characteristics. Results from this review suggest that for acute pain studies, utilizing TOTPAR to assess pain relief may be more sensitive to treatment effects than utilizing SPID to assess pain intensity.

Perspective: The results of this meta-analysis suggest that TOTPAR may be more sensitive to treatment effects than SPIDs are in analgesic trials examining acute pain. We found that standardized effect sizes were higher for TOTPAR compared to SPIDs.

© 2015 by the American Pain Society

Key words: Acute pain, postoperative pain, pain intensity, pain relief, summed pain intensity difference, total pain relief, methodology.

Over the past 20 years, many of the drugs that have progressed to late-phase development have been reformulations of opioids or other molecules

This article was reviewed and approved by the Executive Committee of the ACTION public-private partnership.

The views expressed in this article are those of the authors and no official endorsement by the Food and Drug Administration (FDA) or the pharmaceutical companies that provided unrestricted grants (grant number: U01FD004187) to support the activities of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTION) public-private partnership should be inferred. Financial support for this project was provided by the ACTION public-private partnership, which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, and other sources.

Address reprint requests to Neil Singla, MD, Lotus Clinical Research, 100 W. California Blvd, Unit 25, Pasadena, CA 91105. E-mail: neil@lotuscr.com 1526-5900/\$36.00

© 2015 by the American Pain Society

<http://dx.doi.org/10.1016/j.jpain.2015.03.015>

with known analgesic efficacy.^{32,36} Since the mid-1990s, however, there has been a significant rise in the percentage of negative analgesic clinical investigations.^{16,17,35,64,65} If one assumes that reformulated drugs should generally demonstrate efficacy in phase 3, then why should so many late-phase analgesic investigations have negative results? The precise answer is a matter of ongoing debate, but it is clear that in order for any analgesic investigation to yield a statistically significant treatment benefit, it must 1) test an efficacious product, 2) be properly designed, and 3) be conducted with minimal experimental error.

Acute pain analgesic clinical trials traditionally use 2 different efficacy paradigms, pain intensity and pain relief, to assess treatment effect. The results of a systematic review of acute pain clinical trial methods concluded

that summed pain intensity difference (SPID) and total pain relief (TOTPAR) scores⁷⁴ were comparable in their ability to detect analgesic treatment effects.⁴ However, this study examined only trials of single doses of aspirin, paracetamol, and ibuprofen, and there were only 3 trials for which SPID and TOTPAR could be compared. It is, therefore, currently unclear whether these approaches to assessing efficacy in acute pain trials are generally comparable or whether one of them has greater assay sensitivity to detect treatment effects. For this reason, decisions about the use of these measures are generally made based on expert opinion rather than on empirical evidence (data).

Because of this uncertainty, many acute pain clinical trials utilize both TOTPAR and SPID. The availability of multiple studies that assessed pain outcomes utilizing different paradigms (TOTPAR and SPID) at the same time provides an opportunity to examine which paradigm (pain relief or pain intensity) is more sensitive to treatment effects.

Methods

Data Sources

A systematic electronic search of MEDLINE and the Cochrane Library database was performed by the first and third authors (N.S. and P.D.C.) to identify randomized, double-blind, placebo-controlled clinical trials of analgesics for treatment of acute postoperative pain. The detailed search strategy included the following subject headings and MeSH terms: "acute pain," "randomized," "placebo controlled," "postoperative," "analgesics in adults." The resulting list was intersected with the following group of terms: "pain intensity," "pain assessment," "SPID," "pain relief," and "TOTPAR." Reference lists, meta-analyses, U.S. Food and Drug Administration summary basis of approvals, and clinical trial register databases, including ClinicalTrials.gov, of relevant studies were also manually screened for quantitative data. Titles and abstracts ranging from January 1999 to September 2013 were independently reviewed by the first and third authors (N.S. and P.D.C.) to determine whether each trial met eligibility criteria.

Inclusion and Exclusion Criteria

For inclusion, trials had to be randomized and double-blind with a placebo control group; include participants who suffered from acute postoperative pain of moderate to severe intensity; and measure both pain relief and pain intensity, assessed by TOTPAR and SPID, respectively, at the same time point. The pain measurement scales accepted for the calculation of TOTPAR were an ordinal pain relief scale (eg, none = 0, slight = 1, moderate = 2, good or a lot = 3, and complete = 4) or a continuous visual analog scale with the ends labeled as "no relief" and "complete relief" and no intermediate divisions or descriptive terms. For SPID, the accepted scales were an ordinal pain intensity scale such as the numerical rating scale (eg, 0 = no pain; 10 = worst pain imaginable) or a visual analog scale with the ends labeled "no pain"

and "worst pain imaginable" and no intermediate divisions or descriptive terms. In almost all of the studies, the TOTPAR and SPID data used for our calculations were the prespecified primary or co-primary endpoints. In all cases, the TOTPAR and SPID data used to calculate standard effect sizes (SEs) were from time points after the first administration of study treatment but before the second administration (if multiple doses of study treatment were administered). Publications had to be written in English, subjects had to be 16 years of age or older, and each treatment group in the study had to include at least 10 subjects. Studies were excluded if insufficient information was presented to calculate effect sizes, that is, studies that provided only group means without providing standard deviations or quantities from which standard deviations could be derived (eg, confidence intervals or t-statistics). Other studies that were excluded were those that used active comparators as controls instead of placebos, those that used devices to treat pain, and those that did not examine postoperative acute pain. Even though we did not include the outcome of the trial as an inclusion criterion, our criteria resulted in a pool of articles that did not include any negative trials, possibly because of a bias toward publishing positive clinical trials in medical research.^{15,18,25,33,66,67}

Data Synthesis

Data from the original reports were extracted by the second and third authors (M.H. and P.D.C.), and the following information was coded: number of patients per treatment arm, means and standard deviations for SPID and TOTPAR in each study arm, total number of randomized patients in the trial, surgical procedure, methods of pain measurement, trial sponsor, drug type, number of doses, and time from randomization until the endpoint was measured.

Quantitative data from trials where TOTPAR and SPID data were collected at the same time points were used to calculate SEs. When there were multiple treatment groups with varying dose levels, we chose the treatment group with the highest dose. The SEs were defined as the ratio of the treatment effect (mean value in treatment group minus mean value in control group) to the pooled standard deviation of the outcome variable. For each study, a single time point after the administration of the first dose of study medication, but before the second dose of study medication, was selected. The earliest time point that contained both SPID and TOTPAR data was used. An SE was calculated at that time point for both SPID and TOTPAR.

For trials that met all eligibility criteria but did not include standard deviations for the treatment and control groups ($n = 4$), standard deviations were calculated based on other information provided in the trial. In 3 trials, standard deviations were calculated for the treatment and control groups based on the standard errors reported for each group. For 1 trial, the pooled standard deviation was calculated based on the reported P value from an independent samples t-test along with the group means and group sample sizes.

Statistical Analysis

The parameter of interest was the TOTPAR – SPID difference in SES. Because the data on the TOTPAR and the SPID were paired (measured in the same subjects), the standard error of the estimated TOTPAR – SPID difference in SES depends on the correlation between the TOTPAR and the SPID.²⁷ In the absence of the individual-level data from each trial, this correlation cannot be estimated. Therefore, formal analyses were performed separately for a range of plausible correlations between the TOTPAR and SPID, specifically, .35 to .65. Based on the estimates and standard errors of the TOTPAR – SPID difference in SES from each study, we performed a random-effects meta-analysis⁷³ using the “meta” package in R (R Foundation for Statistical Computing, Vienna, Austria), which employs the DerSimonian and Laird estimator of the between-study variance.¹⁰

Mixed effects meta-regression analyses⁷³ were performed to investigate whether the TOTPAR – SPID difference in SES was associated with selected trial characteristics. The trial characteristics investigated included procedure type (dental, nondental), the number of subjects randomized in the trial, number of doses planned (single, multiple), time from randomization until the endpoint was measured, and drug type (opioid/tramadol, acetaminophen/nonsteroidal anti-inflammatory drugs). These analyses were performed using the “rma.mv” function in the R package “metaphor,” with each trial characteristic as the independent variable and the TOTPAR – SPID difference in SES as the dependent variable.

Results

Three hundred fifty-one reports were identified from our initial electronic search, of which 139 were excluded because they were duplicates or reviews of studies. Ninety-eight original articles were also excluded because they did not report both SPID and TOTPAR pain outcomes. After excluding studies that failed to meet other eligibility criteria, 45 studies were selected for the meta-analysis (Fig 1 and Table 1).

Of the 45 studies included in our review, 29 (64%) examined subjects having dental surgery, 7 (16%) examined subjects undergoing a bunionectomy, and 9 (20%) examined subjects undergoing other kinds of procedures. Thirty-three trials (73%) were sponsored by industry (eg, pharmaceutical companies), 2 trials (4%) had a nonindustry sponsor (eg, a government agency), and 10 trials (22%) did not report sponsorship of any kind. In terms of drug type, 29 trials (64%) administered acetaminophen or some type of nonsteroidal anti-inflammatory drug, and 16 trials (36%) administered an opioid or tramadol. Forty trials (89%) were single-dose studies, and 4 (9%) were multiple-dose studies (in one trial it was unclear whether only one or multiple doses were administered). The mean randomized sample size was 171 with a standard deviation of 94 (range = 36–540); and the mean time until endpoint was 11.8 hours with a standard deviation of 10.2 hours (range = 6–48 hours).

The primary results of the meta-analysis are presented in Table 2. The estimated mean SES was 1.13 for TOTPAR and 1.02 for SPID. The estimated mean difference between the TOTPAR and SPID SESs of .11 was statistically significant ($P = .01$) regardless of the assumed value of the correlation between the TOTPAR and SPID (in the plausible range of .35–.65).

The mixed effects meta-regression analyses did not detect any significant associations between the TOTPAR – SPID difference in SES and any of the trial characteristics examined (Table 3). Although the estimated TOTPAR – SPID difference in SES was higher in studies with multiple doses (.32) than in single-dose studies (.08–.09), this subgroup difference was not statistically significant ($P > .34$).

Discussion

Pioneers in clinical trial design over the last century have established several reliable design elements that have allowed effective and informative evaluations of acute pain therapies, including randomization, blinding, placebo control, accounting for baseline pain, standardizing pain models (choice of surgery type), and the 2-stopwatch technique.^{19,30,29,47} Published literature clearly demonstrates that the existing methodology of single-dose clinical trials has produced many successful studies.^{4,5,14} Over the past 20 years, however, a surprising number of late-phase analgesic clinical trials have not demonstrated a statistically significant benefit of treatment.^{2,38,76} This situation raises the question, Why are so many late-phase trials negative? Although the answer is a matter of some debate, it is likely that limitations in study design, nonoptimal study execution, chance, and lack of adequate sample size or statistical power⁵¹ all play a role.

Several previous studies have compared SPID and TOTPAR measures in acute pain clinical trials. Moore et al⁵² showed that using SPID and TOTPAR to derive dichotomous outcome measures produced very similar results. In subsequent studies, a significantly lower number needed to treat (ie, greater treatment effect) with TOTPAR than with SPID was found for 1 of 5 drug/dosage comparisons⁴ and for 2 of 10 comparisons of minimum efficacy criteria,⁵⁰ and the investigators concluded that TOTPAR and SPID were comparable in their ability to discriminate between treatments. However, the overall pattern of these results favoring TOTPAR is not inconsistent with our data.

The present study extended previous results by focusing on clinical trials of a wide range of analgesics in which both TOTPAR and SPID had been calculated, using the SES as a measure of the assay sensitivity of these 2 different outcome measures, and finding a significant advantage for TOTPAR. It may be that the SES is a more sensitive index of assay sensitivity than the number needed to treat, which is based on categorizations of responders versus nonresponders.

Pain relief in acute pain clinical trials is generally assessed by TOTPAR, which is a time-weighted measure of total area under the pain relief curve that integrates serial assessments of a subject's pain over a prespecified




Figure 1. PRISMA chart for screened, excluded, and included studies.

time period during the trial. In this review, all assessments of TOTPAR were gathered through the use of a 5-point ordinal scale. The main advantage of the ordinal scale is its simplicity; there are only 5 categories from which subjects choose to indicate their pain relief at that current moment. A theoretical disadvantage of TOTPAR is that subjects have to recall their baseline pain intensity each time they are asked to assess their pain relief. Poor or inaccurate baseline pain recall can potentially render the trial data less dependable, particularly in cases where the times of assessments are farther away from the initial baseline. In the draft guidance for analgesic drug development released by the U.S. Food and Drug Administration in February 2014, this particular limitation of TOTPAR as an efficacy endpoint is mentioned.

Pain intensity in acute pain trials is generally assessed by SPID, a time-weighted sum of pain intensity differ-

ences from baseline. The advantage of SPID is that its accuracy does not rely on recall of baseline pain; the subject simply rates his or her pain intensity "at this current moment." Based on the characteristics of these different outcome measures, our hypothesis, contrary to our actual results, was that pain intensity would be the more sensitive efficacy paradigm. Theoretically, one would assume that reporting current pain intensity, without any recall of baseline pain that may have occurred hours earlier under the influence of residual postsurgical anesthesia, would allow the most accurate evaluation of treatment effect. Why, then, was TOTPAR more sensitive? Perhaps it is because when rating their pain relief, patients consider not only changes in their pain intensity but also any improvements in other domains such as physical functioning or sleep, and such a "composite" rating has greater assay sensitivity. We are

Table 1. Summary Table of Studies Included in the Review

REFERENCE	MODEL	TREATMENT	PIIPR SCALE
Ahdieh et al, 2004 ¹	Knee arthroplasty	Oxymorphone ER	Cat/Cat
Aqua et al, 2007 ³	Abdominal surgery	Oxymorphone IR	Cat/Cat
Chang et al, 2004 ⁶	Dental surgery	Rofecoxib	Cat/Cat
Chang et al, 2004 ⁷	Dental surgery	Etoricoxib	Cat/Cat
Daniels et al, 2010 ⁸	Dental surgery	Diclofenac	NPRS/Cat
Daniels et al, 2011 ⁹	Bunionectomy	Oxycodone HCl/niacin*	VAS/Cat
Desjardins et al, 2000 ¹²	Dental surgery	Butorphanol	Cat/Cat
Desjardins et al, 2004 ¹¹	Bunionectomy	Rofecoxib	Cat/Cat
Desjardins et al, 2007 ¹³	Dental surgery	Rofecoxib	Cat/Cat
Fricke et al, 2002 ²¹	Oral surgery	Tramadol/acetaminophen	Cat/Cat
Fricke et al, 2002 ²²	Oral surgery	Rofecoxib	Cat/Cat
Fricke et al, 2004 ²⁰	Dental surgery	Tramadol/acetaminophen	Cat/Cat
Gatoulis et al, 2012 ²³	Dental surgery	Acetaminophen/codeine*	Cat/Cat
Gimbel and Ahdieh, 2004 ²⁴	Abdominal or pelvic surgery	Oxymorphone IR	Cat/Cat
Haglund et al, 2006 ²⁶	Dental surgery	Cyclooxygenase-2 inhibitor	VAS/Cat
Hersh et al, 2004 ²⁸	Dental surgery	ProSorb DIC	Cat/Cat
Jackson et al, 2004 ³¹	Dental surgery	Rofecoxib	Cat/Cat
Juhl et al, 2006 ³⁴	Dental surgery	IV paracetamol	Cat/Cat
Kleinert et al, 2008 ³⁷	Dental surgery	Tapentadol	Cat/Cat
Korn et al, 2004 ³⁹	Dental surgery	Rofecoxib	Cat/Cat
Kubitzeck, 2003 ⁴⁰	Dental surgery	Diclofenac	Cat/Cat
Litkowski et al, 2005 ⁴¹	Dental surgery	Oxycodone/ibuprofen*	Cat/Cat
Malmstrom et al, 2002 ⁴³	Dental surgery	Rofecoxib	Cat/Cat
Malmstrom et al, 2004 ⁴⁴	Dental surgery	Etoricoxib	Cat/Cat
Malmstrom et al, 2004 ⁴⁵	Dental surgery	Etoricoxib	Cat/Cat
Malmstrom et al, 2005 ⁴²	Dental surgery	Etoricoxib	Cat/Cat
Mehlich, 1998 ⁴⁸	Oral surgery	Bromfenac sodium	Cat/Cat
Moller et al, 2005 ⁴⁹	Dental surgery	Paracetamol	Cat/Cat
Morrison et al, 1999 ⁵³	Dental surgery	Rofecoxib	Cat/Cat
Palangio et al, 2000 ⁵⁴	Dental surgery	Hydrocodone/ibuprofen*	Cat/Cat
Qi et al, 2012 ⁵⁵	Dental surgery	Acetaminophen	VAS/Cat
Rasmussen et al, 2005 ⁵⁶	Knee or hip Replacement	Etoricoxib	Cat/Cat
Reicin et al, 2001 ⁵⁷	Orthopedic surgery	Rofecoxib	Cat/Cat
Riff et al, 2009 ⁵⁸	Bunionectomy	Diclofenac	NPRS/Cat
Schwartz et al, 2007 ⁵⁹	Dental surgery	MK-0703	Cat/Cat
Sinatra et al, 2005 ⁶⁰	Orthopedic surgery	IV acetaminophen	Cat/Cat
Singla et al, 2005 ⁶¹	Abdominal or pelvic surgery	Oxycodone/ibuprofen*	Cat/Cat
Stegmann et al, 2008 ⁶³	Bunionectomy	Tapentadol	Cat/Cat
U.S. Food and Drug Administration ⁶⁸	Dental surgery	Oxycodone/ibuprofen*	Cat/Cat
Van Aken et al, 2004 ⁶⁹	Dental surgery	Propacetamol	Cat/Cat
Van Dyke et al, 2004 ⁷⁰	Dental surgery	Oxycodone/ibuprofen*	Cat/Cat
Webster et al, 2010 ⁷¹	Bunionectomy	Morphine/oxycodone	NPRS/Cat
Wermeling et al, 2005 ⁷²	Dental surgery	Butorphanol tartrate	Cat/Cat
Wininger et al, 2010 ⁷⁵	Abdominal surgery	IV acetaminophen	VAS/Cat
Zuniga et al, 2010 ⁷⁷	Dental surgery	Diclofenac	Cat/Cat

Abbreviations: ER, extended release; Cat, categorical scale; IR, immediate release; NPRS, numeric pain rating scale; VAS, visual analog scale; DIC, diclofenac; IV, intravenous.

NOTE. PIIPR scale indicates the scale with which pain intensity/pain relief was obtained.

*Combination product.

not aware of any qualitative research in which patient interpretations of relief versus intensity scales have been compared. Such studies would be valuable in continuing to evaluate how these 2 different kinds of outcomes can best be used in acute pain trials.

It is important to emphasize that there are multiple considerations when selecting outcome measures for analgesic clinical trials. In the present article, we have emphasized assay sensitivity as measured by the SES, and our results show a statistically significant advantage of TOTPAR versus SPID. For truly efficacious treatments, the use of outcome measures with greater assay sensi-

tivity has the potential to reduce sample sizes and the likelihood of falsely negative results. In any clinical trial, however, it is important to consider the clinical meaningfulness of the estimated treatment effect in addition to its statistical significance for proper interpretation of the results, regardless of the outcome measure used.

Limitations

Because the SPID and the TOTPAR are measured on different scales, the treatment effects were summarized using the SES, a scale-free, commonly used metric that is

Table 2. Results of the Random Effects Meta-Analysis for Different Assumed Correlations Between TOTPAR and SPID

ASSUMED CORRELATION BETWEEN TOTPAR AND SPID	DIFFERENCE IN SES (TOTPAR – SPID)	95% CONFIDENCE INTERVAL	P VALUE
.35	.11	.02, .19	.01
.45	.11	.02, .19	.01
.55	.11	.03, .20	.01
.65	.11	.03, .20	.01

particularly amenable to meta-analysis. However, there are important limitations of our analyses that need to be considered. First, the analyses assumed that the studies were large enough to permit the use of the asymptotic (large-sample) distribution of the estimator of the TOTPAR – SPID difference in SES. This assumption appeared to be reasonable given the sample sizes in the studies included in our review. Second, this large-sample distribution depends on the correlation between the TOTPAR and the SPID, and this value was not available from any of the studies we examined. Our meta-analyses, however, demonstrated that the results depended very little on the value of the correlation that was assumed within a plausible range from .35 to .65.

A third limitation is that the characteristics of the included studies were not homogeneous, which was addressed, in part, by the use of a random effects model in the meta-analysis. One important source of heterogeneity is the differences in the types of surgeries that were studied. Although our sample was too small to examine SES differences between SPID and TOTPAR as a function of type of surgery, previous reviews have found no differ-

ences in analgesic efficacy between dental and postsurgical pain^{4,46}; such analyses, however, do not directly address whether the assay sensitivity of different outcome measures differs among these different conditions. Other important sources of heterogeneity among the trials are in dosing (ie, single vs multiple dose studies) and in the specific drugs studied. Moreover, several studies were omitted from the analysis that did not fulfill eligibility criteria, and there may have been others that were not published; it is not clear how representative the studies included in our analyses were of the intended population of studies. The inclusion of only trials that included both the TOTPAR and the SPID measures may have affected the nature of response on these measures. For example, it may be the case that completing both pain assessments in the same trial influences how patients respond on each measure such that they may respond differently if they had completed only one measure. Future research is needed to address this issue.

In addition, there were no clinical trials included in our analyses that calculated SPID and TOTPAR measures of movement-evoked pain. In a meta-analysis of trials examining acute postoperative pain, Srikandarajah and Gilron⁶² found that patients reported higher levels of acute pain for movement-evoked pain compared to resting pain. Given the important differences between these 2 types of pain, research is needed on differences in assay sensitivity between SPID and TOTPAR measures of evoked pain. It would also be important to systematically examine whether the assay sensitivity of evoked and resting pain outcome measures differs.

Finally, the power of the meta-regression analyses may have been limited because of the relatively small number

Table 3. Results of the Mixed Effects Meta-Regression Analyses of Trial Characteristics for Different Assumed Correlations Between TOTPAR and SPID

VARIABLE	ASSUMED CORRELATION	SUBGROUP	TOTPAR – SPID DIFFERENCE IN SES (95% CI)	SUBGROUP DIFFERENCE OR COEFFICIENT (95% CI)*	P VALUE†
Procedure type	.35	Dental	.12 (.03, .21)	.03 (–.17, .24)	.70
		Nondental	.09 (–.10, .27)		
	.65	Dental	.12 (.04, .20)	.03 (–.17, .23)	.69
		Nondental	.09 (–.10, .27)		
Drug class	.35	Opioid/tramadol	.16 (–.04, .36)	.09 (–.12, .31)	.34
		Acet/NSAID	.06 (–.02, .15)		
	.65	Opioid/tramadol	.15 (–.05, .35)	.08 (–.14, .29)	.45
		Acet/NSAID	.07 (–.00, .15)		
Number of doses	.35	Single	.08 (.01, .15)	–.24 (–.91, .43)	.08
		Multiple	.32 (–.35, .99)		
	.65	Single	.09 (.03, .15)	–.23 (–.90, .44)	.11
		Multiple	.32 (–.35, .99)		
Time endpoint measured (h)	.35	N/A	N/A	–.01 (–.09, .08)	.89
	.65	N/A	N/A	–.01 (–.09, .08)	.86
Sample size	.35	N/A	N/A	–.02 (–.11, .07)	.65
	.65	N/A	N/A	–.03 (–.12, .07)	.56

Abbreviations: CI, confidence interval; Acet, acetaminophen; NSAID, nonsteroidal anti-inflammatory drug; N/A, not applicable.

*For categorical variables, this is the subgroup difference in the TOTPAR – SPID difference in SES. For quantitative variables (time endpoint measured and sample size), this is the change in the TOTPAR – SPID difference associated with a 10-hour increase in the time the endpoint was measured or a 100-subject increase in the sample size, as appropriate.

†P value from a meta-regression analysis testing the null hypothesis that the subgroup difference or coefficient is equal to zero.

of studies in some of the subgroups examined. The finding that there were no trial characteristics that were statistically significantly associated with the TOTPAR – SPID difference in SES does not completely rule out such associations, as indicated by the widths of the confidence intervals in [Table 3](#).

Conclusions

Thoughtful analysis and exploration of analgesic clinical trial design elements have been spearheaded by groups such as the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the U.S. Food

and Drug Administration. Many recent publications have focused on methodological concerns relevant to the assay sensitivity of chronic pain studies.^{16,17,19,35} However, the concerns are analogous for acute pain, and the reevaluation of methodologies used in acute pain trials would seem to be valuable. Our results suggest an important avenue for future research in terms of the need to prospectively examine the assay sensitivity of pain relief versus pain intensity in clinical trials. Additionally, future research should address whether differences in assay sensitivity between these 2 types of measures are present for chronic pain trials and for pain treatments other than analgesics (eg, nerve blocks, physical therapy, acupuncture, cognitive-behavioral therapy).

References

- Ahdieh H, Ma T, Babul N, Lee D: Efficacy of oxymorphone extended release in postsurgical pain: A randomized clinical trial in knee arthroplasty. *J Clin Pharmacol* 44:767-776, 2004
- Arrowsmith J: Trial Watch: Phase III and submission failures: 2007-2010. *Nat Rev Drug Discov* 10:87, 2011
- Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R: Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: A randomized, double-blind, active- and placebo-controlled, parallel-group trial. *Clin Ther* 29:1000-1012, 2007
- Barden J, Edwards JE, Mason L, McQuay HJ, Moore RA: Outcomes in acute pain trials: Systematic review of what was reported? *Pain* 109:351-356, 2004
- Beecher HK: The measurement of pain. *Pharmacol Rev* 9: 59-210, 1957
- Chang DJ, Desjardins PJ, Bird SR, Black P, Chen E, Petruschke RA, Geba GP: Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: A randomized controlled trial. *Curr Med Res Opin* 20:939-949, 2004
- Chang DJ, Desjardins PJ, King TR, Erb T, Geba G: The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: A randomized, double-blind clinical trial. *Anesth Analg* 99: 807-815, 2004
- Daniels SE, Baum DR, Clark F, Golf MH, McDonnell ME, Boesing SE: Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain. *Curr Med Res Opin* 26:2375-2384, 2010
- Daniels SE, Spivey RJ, Singla S, Golf M, Clark FJ: Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. *Curr Med Res Opin* 27:593-603, 2011
- DerSimonian R, Laird N: Meta-analysis in clinical trials. *Control Clin Trials* 7:177-188, 1986
- Desjardins PJ, Black PM, Daniels S, Bird SR, Fitzgerald BJ, Petruschke RA, Tershakovec A, Chang DJ: A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. *Curr Med Res Opin* 20:1523-1537, 2004
- Desjardins PJ, Black PM, Daniels SE, Bird SR, Petruschke RA, Chang DJ, Smugar SS, Tershakovec AM: Double-blind randomized controlled trial of rofecoxib and multidose oxycodone/acetaminophen in dental impaction pain. *J Oral Maxillofac Surg* 65:1624-1632, 2007
- Desjardins PJ, Norris LH, Cooper SA, Reynolds DC: Analgesic efficacy of intranasal butorphanol (Stadol NS) in the treatment of pain after dental impaction surgery. *J Oral Maxillofac Surg* 58:19-26, 2000
- DiMasi JA: Risks in new drug development: Approval success rates for investigational drugs. *Clin Pharmacol Ther* 69:297-307, 2001
- Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PH, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. *PLoS One* 3:e3081, 2008
- Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. *Pain* 149:177-193, 2010
- Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja M, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C: Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. *Pain* 153:1148-1158, 2012
- Fanelli D: Negative results are disappearing from most disciplines and countries. *Scientometrics* 90:891-904, 2012
- Farrar JT: Advances in clinical research methodology for pain clinical trials. *Nat Med* 16:1284-1293, 2010
- Fricke JR, Hewitt DJ, Jordan DM, Fisher A, Rosenthal NR: A double-blind placebo-controlled comparison of tramadol/acetaminophen and tramadol in patients with postoperative dental pain. *Pain* 109:250-257, 2004
- Fricke JR, Karim R, Jordan D, Rosenthal N: A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets,

hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. *Clin Ther* 24:953-968, 2002

22. Fricke J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP, Verburg KM: Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. *Am J Ther* 9:89-97, 2002

23. Gatoulis SC, Voelker M, Fisher M: Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: Results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain. *Clin Ther* 34:138-148, 2012

24. Gimbel J, Ahdieh H: The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. *Anesth Analg* 99:1472-1477, 2004

25. Gotzsche PC: Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 12:249, 2011

26. Haglund B, Bülzingerslöwen I: Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: A randomized, double-blind, placebo-controlled study. *Eur J Oral Sci* 114:293-301, 2006

27. Hedges LV, Olkin I: *Statistical Methods for Meta-analysis*. Orlando, FL, Academic Press, 1985

28. Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, Watson G, Lyon JA: Dose-ranging analgesic study of ProSorb diclofenac potassium in postsurgical dental pain. *Clin Ther* 26:1215-1227, 2004

29. Houde RW: On appraising pain and analgesic drugs. In: Keele CA, Smith R (eds): *The Assessment of Pain in Man and Animals*. Edinburgh, Livingstone, 1962, pp 202-212

30. Houde RW, Wallenstein SL, Rogers A: Clinical pharmacology of analgesics. 1. A method of assaying analgesic effect. *Clin Pharmacol Ther* 1:163-174, 1960

31. Jackson ID, Heidemann BH, Wilson J, Brown RD: Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. *Br J Anaesth* 92:675-680, 2004

32. Jadad AR, Carroll D, Moore A, McQuay H: Developing a database of published reports of randomized clinical trials in pain research. *Pain* 66:239-246, 1996

33. Joober R, Schimitz N, Annable L, Boska P: Publication bias: What are the challenges and can they be overcome? *J Psychiatry Neurosci* 37:149-152, 2012

34. Juhl GI, Norholt SE, Tonnesen E, Hiesse-Provost O, Jensen TS: Analgesic efficacy and safety of intravenous paracetamol (acetaminophen) administered as a 2 g starting dose following third molar surgery. *Eur J Pain* 10:371-377, 2006

35. Katz N: Methodological issues in clinical trials of opioid for chronic pain. *Neurology* 65:332-349, 2005

36. Kissin I: The development of new analgesics over the past 50 years: A lack of real breakthrough drugs. *Anesth Analg* 110:780-789, 2010

37. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P: Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized double-blind, placebo-controlled study. *Anesth Analg* 107:2048-2055, 2008

38. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates. *Nat Rev Drug Discov* 3:711-715, 2004

39. Korn S, Vassil TC, Kotey PN, Fricke JR: Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: A randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. *Clin Ther* 26:769-778, 2004

40. Kubitzek F, Ziegler G, Gold M, Liu J, Ionescu E: Analgesic efficacy of low-dose diclofenac versus paracetamol. *J Orofac Pain* 17:237-244, 2003

41. Litkowski LJ, Christensen SE, Adamson DN, Dyke TV, Han S, Newman KB: Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: A randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model. *Clin Ther* 27:418-429, 2005

42. Malmstrom K, Ang J, Fricke JR, Shingo S, Reicin A: The analgesic effect of etoricoxib relative to that of two opioid-acetaminophen analgesics: A randomized, controlled single-dose study in acute dental impaction pain. *Curr Med Res Opin* 21:141-149, 2005

43. Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B: A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: A single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. *Clin Ther* 24:1549-1560, 2002

44. Malmstrom K, Kotey P, Coughlin H, Desjardins PJ: A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. *Clin J Pain* 20:147-155, 2004

45. Malmstrom K, Sapre A, Coughlin H, Agrawal NGB, Mazonko RS, Fricke JR: Etoricoxib in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. *Clin Ther* 26:667-679, 2004

46. McQuay HJ, Derry S, Eccleston C, Wiffen PJ, Moore RA: Evidence for analgesic effect in acute pain—50 years on. *Pain* 153:1364-1367, 2012

47. McQuay HJ, Moore RA. *Methods of Therapeutic Trials*. Available at: www.medicine.ox.ac.uk/bandolier/CH18ToPmethods.pdf. Accessed February, 15, 2015

48. Mehlisch DR: Double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery. *J Clin Pharmacol* 38:455, 1998

49. Moller PL, Juhl GI, Payen-Champenois C, Skoglund LA: Intravenous acetaminophen (paracetamol): Comparable analgesic efficacy, but better local safety than its prodrug, propacetamol, for postoperative pain after third molar surgery. *Anesth Analg* 101:90-96, 2005

50. Moore RA, Derry S, McQuay HJ, Wiffen PJ: Single dose oral analgesics for acute postoperative pain in adults. *Cochrane Database of Systematic Reviews* 2011, Issue 9. Art. No.: CD008659. DOI: <http://dx.doi.org/10.1002/14651858.CD008659.pub2>

51. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ: Size is everything—Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. *Pain* 78:209-216, 1998

52. Moore RA, McQuay H, Gavaghan D: Deriving dichotomous outcome measures from continuous data in randomized controlled trials of analgesics: Verification from independent data. *Pain* 69:127-130, 1997
53. Morrison BW, Christensen S, Yuan W, Brown J, Almani S, Seidenberg B: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. *Clin Ther* 21:943-953, 1999
54. Palangio M, Wideman GL, Keffer M, Landau CJ, Morns E, Doyle RT Jr, Jiang JG, Damask M, de Padova A: Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic pain. *Clin Ther* 22:600-612, 2000
55. Qi DS, May LG, Zimmerman B, Peng P, Atillasoy E, Brown JD, Cooper SA: A randomized, double-blind, placebo-controlled study of acetaminophen 1000 mg versus acetaminophen 650 mg for the treatment of postsurgical dental pain. *Clin Ther* 34:2247-2258e3, 2012
56. Rasmussen GL, Malmstrom K, Bourne MH, Jove M, Rhondeau SM, Kotey P, Ang J, Aversano M, Reicin A: Etoricoxib Postorthopedic Study Group: Etoricoxib provides analgesic efficacy to patients after knee or hip replacement surgery: A randomized, double-blind, placebo-controlled study. *Anesth Analg* 101:1104-1111, 2005
57. Reicin A, Brown J, Jove M, deAndrade JR, Bourne M, Walters D, Seidenberg B: Efficacy of single-dose and multi-dose rofecoxib in the treatment of post-orthopedic surgery pain. *Am J Orthop* 30:40-48, 2001
58. Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE: Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: A phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. *Clin Ther* 31:2072-2085, 2009
59. Schwartz JI, Kotey PN, Fricke JR, Gottesdiener K: MK-0703 (a cyclooxygenase-2 inhibitor) in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. *Am J Ther* 14:13-19, 2007
60. Sinatra RS, Jahr JS, Reynolds LW, Jahr J, Reynolds L, Viscusi E, Groudline S, Payen-Champenois C: Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. *Anesthesiology* 102:822-831, 2005
61. Singla N, Pong A, Newman K, MD-10 Study Group: Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: A randomized, double-blind, placebo- and active-controlled parallel-group study. *Clin Ther* 27:45-57, 2005
62. Srikandarajah S, Gilron I: Systematic review of movement-evoked pain versus pain at reset in postsurgical clinical trials and meta-analyses: A fundamental distinction requiring standardized measurement. *Pain* 152:1734-1739, 2011
63. Stegmann J, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S: The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. *Curr Med Res Opin* 24:3185-3196, 2008
64. Thienel U, Neto W, Schwabe SK: Topiramate in painful diabetic polyneuropathy: Findings from three double-blind placebo-controlled trials. *Acta Neurol Scand* 100:221-231, 2004
65. Turner HM, Bernard RM: Calculating and synthesizing effect sizes. *Contemp Iss Commun Disord* 33:42-55, 2006
66. Turner EH, Knoepflmacher D, Shapley L: Publication bias in antipsychotic trials: An analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS Med* 9:e1001189, 2012
67. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 358:252-260, 2008
68. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Combunox NDA# 21-378. Statistical review. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021378s000_CombunoxTOC.cfm. Accessed February, 1, 2013
69. Van Aken H, Thys L, Veekman L, Buerkle H: Assessing analgesia in single and repeated administrations of propacetamol for postoperative pain: Comparison with morphine after dental surgery. *Anesth Analg* 98:159-165, 2004
70. Van Dyke T, Litkowski LJ, Kiersch TA, Zarringhalam NM, Zheng H, Newman K: Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: A double-blind, placebo- and active-controlled parallel-group study. *Clin Ther* 26:2003-2014, 2004
71. Webster L, Richards P, Stern W, Kelen R: A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. *J Opioid Manag* 6:329-340, 2010
72. Wermeling DP, Grant GM, Lee A, Alexander N, Rudy AC: Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: A randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 27:430-440, 2005
73. Whitehead A: Meta-Analysis of Controlled Clinical Trials. Chichester, West Sussex, UK, John Wiley and Sons, 2003
74. Williamson A, Hoggart B: Pain: A review of three commonly used pain rating scales. *J Clin Nurs* 14:798-804, 2005
75. Winger SJ, Miller H, Minkowitz HS, Minkowitz HS, Roval MA, Ang RY, Breitmeyer JB, Singla NK: A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. *Clin Ther* 32:2348-2369, 2010
76. Woolf CJ: Overcoming obstacles to developing new analgesics. *Nat Med* 16:1241-1247, 2010
77. Zuniga JR, Malmstrom H, Noveck RJ, Campbell JH, Christensen S, Glickman RS, Tomasetti BJ, Boesing SE: Controlled phase III clinical trial of diclofenac potassium liquid-filled soft gelatin capsule for treatment of postoperative dental pain. *J Oral Maxillofac Surg* 68:2735-2742, 2010